Is TMO a Buy? What to Consider in 2026

The case for Thermo Fisher Scientific right now is Bioprocessing and Biologic Drug Manufacturing Tailwind, with revenue (full year 2025) at ~$44.6 billion. If you believe that thesis holds, TMO is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical an

The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, the stock's valuation, though below its own ten-year average on a trailing price-to-earnings basis, still prices in sustained mid-single-digit organic growth, leaving limited room for disappointment if end markets soften.

Thermo Fisher Scientific makes scientific instruments, consumables, reagents, and provides services used in pharmaceutical drug development, biological research, clinical diagnostics, and environmental testing. Its four segments cover Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, with brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon, and PPD.

That depends on your investment horizon, risk tolerance, and existing portfolio exposure to healthcare and life sciences. TMO trades at a trailing P/E of roughly 26x, below its own ten-year average, which some investors view as a more attractive entry point relative to history. Others note that organic revenue growth has been modest in recent quarters. Whether that setup suits your goals is a personal decision, not a universal answer.

Yes, Thermo Fisher pays a quarterly cash dividend and has maintained dividend payments for more than 13 consecutive years. The company raised its dividend by 10 percent in early 2025 and has grown it for at least six consecutive years. The dividend yield is relatively modest given the stock's price, reflecting management's preference for returning capital through share repurchases and funding acquisitions alongside dividend payments.

TMO's primary competitors include Danaher (bioprocessing and diagnostics), Agilent Technologies and Waters Corporation (analytical instruments and chromatography), Illumina (genomic sequencing), and MilliporeSigma, the life science unit of Merck KGaA (bioprocess consumables and lab chemicals). No single competitor matches Thermo Fisher's breadth, but each holds strong positions in specific niches.